The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.

Subjects

Subjects :

Humans
Nivolumab therapeutic use
Ipilimumab therapeutic use
Proto-Oncogene Proteins B-raf genetics
France
Antineoplastic Combined Chemotherapy Protocols
Melanoma drug therapy
Melanoma genetics
Skin Neoplasms drug therapy
Skin Neoplasms genetics

Details

Language :

English

ISSN :

0151-9638

Volume :

151

Issue :

1

Database :

MEDLINE

Journal :

Annales de dermatologie et de venereologie

Publication Type :

Editorial & Opinion

Accession number :

38325268

Full Text :

https://doi.org/10.1016/j.annder.2023.103243